{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,4,13]],"date-time":"2023-04-13T08:29:11Z","timestamp":1681374551107},"reference-count":77,"publisher":"Oxford University Press (OUP)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur Heart J"],"published-print":{"date-parts":[[2016,2,7]]},"DOI":"10.1093\/eurheartj\/ehv721","type":"journal-article","created":{"date-parts":[[2016,1,12]],"date-time":"2016-01-12T01:13:19Z","timestamp":1452561199000},"page":"510-519","source":"Crossref","is-referenced-by-count":8,"title":["The year in cardiology 2015: prevention"],"prefix":"10.1093","volume":"37","author":[{"given":"M. John","family":"Chapman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Blankenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulf","family":"Landmesser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2016,1,3]]},"reference":[{"key":"2016020700322489000_37.6.510.1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv428"},{"key":"2016020700322489000_37.6.510.2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehs092"},{"key":"2016020700322489000_37.6.510.3","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehr158"},{"key":"2016020700322489000_37.6.510.4","doi-asserted-by":"crossref","unstructured":"Avanzini F , Marzona I , Baviera M , Barlera S , Milani V , Caimi V , Longoni P , Tombesi M , Silletta MG , Tognoni G , Roncaglioni MC ; Risk and Prevention Study Collaborative Group. Improving cardiovascular prevention in general practice: Results of a comprehensive preventive strategy in subjects at high risk. Eur J Prev Cardiol 2015; pii: 2047487315613664. [Epub ahead of print].","DOI":"10.1177\/2047487315613664"},{"key":"2016020700322489000_37.6.510.5","doi-asserted-by":"crossref","unstructured":"Lachman S , Peters RJ , Lentjes MA , Mulligan AA , Luben RN , Wareham NJ , Khaw KT , Boekholdt SM . Ideal cardiovascular health and risk of cardiovascular events in the EPIC-Norfolk prospective population study. Eur J Prev Cardiol 2015; pii: 2047487315602015. [Epub ahead of print].","DOI":"10.1177\/2047487315602015"},{"key":"2016020700322489000_37.6.510.6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)17018-9"},{"key":"2016020700322489000_37.6.510.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2015.06.008"},{"key":"2016020700322489000_37.6.510.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2012.09.017"},{"key":"2016020700322489000_37.6.510.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2015.02.020"},{"key":"2016020700322489000_37.6.510.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1410489"},{"key":"2016020700322489000_37.6.510.11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61350-5"},{"key":"2016020700322489000_37.6.510.12","doi-asserted-by":"publisher","DOI":"10.1097\/MOL.0000000000000230"},{"key":"2016020700322489000_37.6.510.13","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv349"},{"key":"2016020700322489000_37.6.510.14","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv236"},{"key":"2016020700322489000_37.6.510.15","doi-asserted-by":"publisher","DOI":"10.1097\/MOL.0000000000000239"},{"key":"2016020700322489000_37.6.510.16","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.114.014310"},{"key":"2016020700322489000_37.6.510.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2015.01.017"},{"key":"2016020700322489000_37.6.510.18","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv029"},{"key":"2016020700322489000_37.6.510.19","doi-asserted-by":"crossref","unstructured":"Iannaccone M , Quadri G , Taha S , D'Ascenzo F , Montefusco A , Omede\u2019 P , Jang IK , Niccoli G , Souteyrand G , Yundai C , Toutouzas K , Benedetto S , Barbero U , Annone U , Lonni E , Imori Y , Biondi-Zoccai G , Templin C , Moretti C , Luscher TF , Gaita F . Prevalence and predictors of culprit plaque rupture at OCT in patients with coronary artery disease: a meta-analysis. Eur Heart J Cardiovasc Imaging 2015; doi:10.1093\/ehjci\/jev283 .","DOI":"10.1093\/ehjci\/jev283"},{"key":"2016020700322489000_37.6.510.20","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61730-X"},{"key":"2016020700322489000_37.6.510.21","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.115.015744"},{"key":"2016020700322489000_37.6.510.22","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/eht406"},{"key":"2016020700322489000_37.6.510.23","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.114.014522"},{"key":"2016020700322489000_37.6.510.24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1415921"},{"key":"2016020700322489000_37.6.510.25","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv043"},{"key":"2016020700322489000_37.6.510.26","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms6068"},{"key":"2016020700322489000_37.6.510.27","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.114.304477"},{"key":"2016020700322489000_37.6.510.28","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/eht273"},{"key":"2016020700322489000_37.6.510.29","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehu274"},{"key":"2016020700322489000_37.6.510.30","doi-asserted-by":"publisher","DOI":"10.1016\/S1567-5688(15)50006-8"},{"key":"2016020700322489000_37.6.510.31","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv157"},{"key":"2016020700322489000_37.6.510.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2015.02.006"},{"key":"2016020700322489000_37.6.510.33","doi-asserted-by":"publisher","DOI":"10.1038\/nrcardio.2014.84"},{"key":"2016020700322489000_37.6.510.34","unstructured":"Food and Drug Administration Center for Drug Evaluation and Research. The Endocrinologic and Metabolic Drugs Advisory Committee Meeting. 9 June 2015. Briefing document BLA 125559. Praluent (alirocumab) injection. http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/EndocrinologicandMetabolicDrugsAdvisoryCommittee\/UCM449867 ( 3 November 2015 )."},{"key":"2016020700322489000_37.6.510.35","unstructured":"Food and Drug Administration Center for Drug Evaluation and Research. The Endocrinologic and Metabolic Drugs Advisory Committee Meeting. June 10, 2015. Briefing document. Repatha (evolocumab) injection. http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/EndocrinologicandMetabolicDrugsAdvisoryCommittee\/UCM450072.pdf ( 3 November 2015 )."},{"key":"2016020700322489000_37.6.510.36","doi-asserted-by":"crossref","first-page":"A18390","DOI":"10.1161\/circ.132.suppl_3.18390","article-title":"Effects of a proprotein convertase subtilisin\/kexin type 9 (PCSK9) inhibitor, alirocumab, on lipid and lipoprotein metabolism in healthy subjects","volume":"132","author":"Reyes-Soffer","year":"2015","journal-title":"Circulation"},{"issue":"(Abstract supplement)","key":"2016020700322489000_37.6.510.37","first-page":"309","article-title":"A phase 1, randomized, placebo-controlled, single ascending and multiple dose study of subcutaneously administered ALN-PCSSC in subjects with elevated low density lipoprotein cholesterol","volume":"36","author":"Fitzgerald","year":"2015","journal-title":"Eur Heart J"},{"key":"2016020700322489000_37.6.510.38","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv174"},{"key":"2016020700322489000_37.6.510.39","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61399-4"},{"key":"2016020700322489000_37.6.510.40","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehu482"},{"key":"2016020700322489000_37.6.510.41","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv370"},{"key":"2016020700322489000_37.6.510.42","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.115.307071"},{"key":"2016020700322489000_37.6.510.43","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-015-3528-5"},{"key":"2016020700322489000_37.6.510.44","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1500858"},{"key":"2016020700322489000_37.6.510.45","doi-asserted-by":"crossref","first-page":"A16863","DOI":"10.1161\/circ.132.suppl_3.16863","article-title":"Alirocumab effect on glycemic measures in patients without diabetes at baseline","volume":"132","author":"Colhoun","year":"2015","journal-title":"Circulation"},{"key":"2016020700322489000_37.6.510.46","doi-asserted-by":"crossref","first-page":"A17070","DOI":"10.1161\/circ.132.suppl_3.17070","article-title":"Efficacy and safety of alirocumab: pooled analyses of 1048 individuals with diabetes mellitus from five placebo-controlled Phase 3 studies of at least 52 weeks duration","volume":"132","author":"Ginsberg","year":"2015","journal-title":"Circulation"},{"key":"2016020700322489000_37.6.510.47","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2014.02.615"},{"key":"2016020700322489000_37.6.510.48","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501031"},{"key":"2016020700322489000_37.6.510.49","doi-asserted-by":"crossref","first-page":"A19109","DOI":"10.1161\/circ.132.suppl_3.19109","article-title":"Low PCSK9 and LDL cholesterol and risk of dementia, Parkinson's disease, and epilepsy\u2014a Mendelian randomization study","volume":"132","author":"Benn","year":"2015","journal-title":"Circulation"},{"key":"2016020700322489000_37.6.510.50","unstructured":"EBBINGHAUS: Evaluating PCSK9 Binding antiBody Influence oN coGnitive HeAlth in High cardiovascUlar Risk Subjects. ClinicalTrials.gov Identifier: NCT02207634 . https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02207634 ( 3 November 2015 )."},{"key":"2016020700322489000_37.6.510.51","doi-asserted-by":"publisher","DOI":"10.1097\/MOL.0000000000000171"},{"key":"2016020700322489000_37.6.510.52","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.113.007012"},{"key":"2016020700322489000_37.6.510.53","doi-asserted-by":"publisher","DOI":"10.7326\/M14-2957"},{"key":"2016020700322489000_37.6.510.54","unstructured":"SPIRE-1: The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects. ClinicalTrials.gov Identifier: NCT01975376 . https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01975376 ( 3 November 2015 )."},{"key":"2016020700322489000_37.6.510.55","unstructured":"SPIRE-2: The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects. ClinicalTrials.gov Identifier: NCT01975389 . https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01975389 ( 3 November 2015 )."},{"key":"2016020700322489000_37.6.510.56","unstructured":"FOURIER: Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk. ClinicalTrials.gov Identifier: NCT01764633 . https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01764633 ( 3 November 2015 )."},{"key":"2016020700322489000_37.6.510.57","unstructured":"ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553 (REGN727). ClinicalTrials.gov Identifier: NCT01663402 . https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01663402 (3 November 2015) ."},{"key":"2016020700322489000_37.6.510.58","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehq386"},{"key":"2016020700322489000_37.6.510.59","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2012.04.038"},{"key":"2016020700322489000_37.6.510.60","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2015.07.020"},{"key":"2016020700322489000_37.6.510.61","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.115.016757"},{"key":"2016020700322489000_37.6.510.62","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2014.01.006"},{"key":"2016020700322489000_37.6.510.63","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2014.05.060"},{"key":"2016020700322489000_37.6.510.64","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M114.611988"},{"key":"2016020700322489000_37.6.510.65","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1016\/S0140-6736(15)61252-1","article-title":"Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study","volume":"386","author":"Tsimikas","year":"2010","journal-title":"Lancet"},{"key":"2016020700322489000_37.6.510.66","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(13)70191-8"},{"key":"2016020700322489000_37.6.510.67","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehr112"},{"key":"2016020700322489000_37.6.510.68","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2014.09.042"},{"key":"2016020700322489000_37.6.510.69","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1400283"},{"key":"2016020700322489000_37.6.510.70","doi-asserted-by":"crossref","first-page":"A17086","DOI":"10.1161\/circ.132.suppl_3.17086","article-title":"Alirocumab LDL-C-lowering efficacy in patients with moderate CKD","volume":"132","author":"Toth","year":"2015","journal-title":"Circulation"},{"key":"2016020700322489000_37.6.510.71","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504720"},{"key":"2016020700322489000_37.6.510.72","doi-asserted-by":"crossref","unstructured":"Williams B , MacDonald TM , Morant S , Webb DJ , Sever P , McInnes G , Ford I , Cruickshank JK , Caulfield MJ , Salsbury J , Mackenzie I , Padmanabhan S , Brown MJ ; British Hypertension Society's PATHWAY Studies Group. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet 2015; doi:10.1016\/S0140-6736(15)00257-3 .","DOI":"10.1016\/S0140-6736(15)00257-3"},{"key":"2016020700322489000_37.6.510.73","doi-asserted-by":"crossref","unstructured":"Brown MJ , Williams B , Morant SV , Webb DJ , Caulfield MJ , Cruickshank JK , Ford I , McInnes G , Sever P , Salsbury J , Mackenzie IS , Padmanabhan S , MacDonald TM ; British Hypertension Society's Prevention; Treatment of Hypertension with Algorithm-based Therapy (PATHWAY) Studies Group. Effect of amiloride, or amiloride plus hydrochlorothiazide, versus hydrochlorothiazide on glucose tolerance and blood pressure (PATHWAY-3): a parallel-group, double-blind randomised phase 4 trial. Lancet Diabetes Endocrinol 2015; doi:10.1016\/S2213-8587(15)00377-0 .","DOI":"10.1016\/S2213-8587(15)00377-0"},{"key":"2016020700322489000_37.6.510.74","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61942-5"},{"key":"2016020700322489000_37.6.510.75","unstructured":"The SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 2015 [Epub ahead of print]."},{"key":"2016020700322489000_37.6.510.76","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110874"},{"key":"2016020700322489000_37.6.510.77","doi-asserted-by":"publisher","DOI":"10.1001\/jama.295.13.jpc60002"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/eurheartj\/article-pdf\/37\/6\/510\/7470272\/ehv721.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T11:40:25Z","timestamp":1654083625000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-lookup\/doi\/10.1093\/eurheartj\/ehv721"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,3]]},"references-count":77,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2016,2,7]]},"published-print":{"date-parts":[[2016,2,7]]}},"alternative-id":["10.1093\/eurheartj\/ehv721"],"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehv721","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1,3]]}}}